Paper32079263
Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.
Batista-Duharte A and 5 others. Biomolecules, 2020. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement. Papers, record 32079263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32079263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adjuvants, Immunologic | Major topic |
| Immunity | Major topic |
| Oligonucleotides, Antisense | Major topic |
| Animals | |
| Humans | |
| Vaccination | |
| Vaccines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| FAPESP, Grant Number: 2018/15187-2 | Fundação de Amparo à Pesquisa do Estado de São Paulo | International | PubMed |
Source PubMed
References150
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31836192 | Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017-2019. | Trends Pharmacol Sci | 2020 | https://conductscience.org/library/papers/31836192 | PubMed |
| 2 | 30138565 | T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas. | Mol Pharm | 2018 | https://conductscience.org/library/papers/30138565 | PubMed |
| 3 | 16517711 | Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. | J Immunol | 2006 | https://conductscience.org/library/papers/16517711 | PubMed |
| 4 | 9009250 | Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. | Leuk Res | 1996 | https://conductscience.org/library/papers/9009250 | PubMed |
| 5 | 5307809 | The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. | Proc Natl Acad Sci U S A | 1969 | https://conductscience.org/library/papers/5307809 | PubMed |
| 6 | 17172312 | Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. | Drug Metab Dispos | 2007 | https://conductscience.org/library/papers/17172312 | PubMed |
| 7 | 8168141 | MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. | Cell Immunol | 1994 | https://conductscience.org/library/papers/8168141 | PubMed |
| 8 | 16972901 | Immune resistance orchestrated by the tumor microenvironment. | Immunol Rev | 2006 | https://conductscience.org/library/papers/16972901 | PubMed |
| 9 | 11365956 | Fomivirsen approved for CMV retinitis. | J Int Assoc Physicians AIDS Care | 1998 | https://conductscience.org/library/papers/11365956 | PubMed |
| 10 | 26283035 | A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. | Eur J Cancer | 2015 | https://conductscience.org/library/papers/26283035 | PubMed |
| 11 | 31195692 | TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31195692 | PubMed |
| 12 | 24798406 | Oligonucleotide delivery: a patent review (2010 - 2013). | Expert Opin Ther Pat | 2014 | https://conductscience.org/library/papers/24798406 | PubMed |
| 13 | 25666165 | Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. | Adv Drug Deliv Rev | 2015 | https://conductscience.org/library/papers/25666165 | PubMed |
| 14 | 6200641 | Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. | J Natl Cancer Inst | 1984 | https://conductscience.org/library/papers/6200641 | PubMed |
| 15 | 22051890 | Vaccines for the twenty-first century society. | Nat Rev Immunol | 2011 | https://conductscience.org/library/papers/22051890 | PubMed |
| 16 | 25994601 | Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics. | Expert Opin Drug Deliv | 2015 | https://conductscience.org/library/papers/25994601 | PubMed |
| 17 | 8476504 | Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. | Anticancer Drug Des | 1993 | https://conductscience.org/library/papers/8476504 | PubMed |
| 18 | 8615886 | Effect of different chemically modified oligodeoxynucleotides on immune stimulation. | Biochem Pharmacol | 1996 | https://conductscience.org/library/papers/8615886 | PubMed |
| 19 | 12489851 | Antisense oligonucleotides: basic concepts and mechanisms. | Mol Cancer Ther | 2002 | https://conductscience.org/library/papers/12489851 | PubMed |
| 20 | 29175113 | Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal. | Pharmacol Res | 2018 | https://conductscience.org/library/papers/29175113 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42974492 | Gene-Specific Antisense Oligonucleotide Therapy Targeting AMA1: A Potential Malaria Treatment. | Iran J Parasitol | 2026 | https://conductscience.org/library/papers/42974492 | PubMed |
| 42938726 | Comparative Analysis of Inhibition Efficiency of Chimeric Antisense Oligonucleotides with Various Chemical Modifications and Their Application for Exogenous Control of Gene Expression in Escherichia coli. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938726 | PubMed |
| 42801377 | Silencing with precision: In silico strategies for antisense oligonucleotide engineering. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42801377 | PubMed |
| 42728797 | Recent Advancements in Drug Delivery Across the Blood-Brain Barrier in Amyotrophic Lateral Sclerosis (ALS). | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/42728797 | PubMed |
| 42651807 | Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42651807 | PubMed |
| 42042810 | CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant Sporothrix spp. Enolase Antigen. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42042810 | PubMed |
| 39936282 | An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. | Future Oncol | 2025 | https://conductscience.org/library/papers/39936282 | PubMed |
| 39385255 | Advances and applications of RNA vaccines in tumor treatment. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39385255 | PubMed |
| 39356099 | Polymeric Vehicles for Nucleic Acid Delivery: Enhancing the Therapeutic Efficacy and Cellular Uptake. | Recent Adv Drug Deliv Formul | 2024 | https://conductscience.org/library/papers/39356099 | PubMed |
| 39272802 | Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39272802 | PubMed |
| 38422397 | Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability. | Mol Pharm | 2024 | https://conductscience.org/library/papers/38422397 | PubMed |
| 38228506 | Heterochiral modifications enhance robustness and function of DNA in living human cells. | Chembiochem | 2024 | https://conductscience.org/library/papers/38228506 | PubMed |
| 38044945 | Antisense oligonucleotides: a novel Frontier in pharmacological strategy. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38044945 | PubMed |
| 37099227 | Combined Application of Antisense Oligomers to Control Transcription Factors of Candida albicans Biofilm Formation. | Mycopathologia | 2023 | https://conductscience.org/library/papers/37099227 | PubMed |
| 37006713 | Analysis of key genes in Mycobacterium ulcerans reveals conserved RNA structural motifs and regions with apparent pressure to remain unstructured. | Front Trop Dis | 2022 | https://conductscience.org/library/papers/37006713 | PubMed |
| 36791960 | A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. | J Adv Res | 2023 | https://conductscience.org/library/papers/36791960 | PubMed |
| 36694567 | Potential of RH5 Antisense on Plasmodium falciparum Proliferation Abatement. | Iran J Parasitol | 2022 | https://conductscience.org/library/papers/36694567 | PubMed |
| 36016952 | The dark side of Tregs during aging. | Front Immunol | 2022 | https://conductscience.org/library/papers/36016952 | PubMed |
| 36015348 | Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36015348 | PubMed |
| 35628649 | Study of Oligonucleotides Access and Distribution in Human Peripheral Blood Mononuclear Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35628649 | PubMed |
Genes31
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32079263
GET https://conductscience.org/api/papers/v1/32079263/references?page=2